Mikrobiota kishechnika i vozmozhnosti probioticheskoy terapii pri vospalitel'nykh zabolevaniyakh kishechnika
- Authors: Kornienko E.A1
-
Affiliations:
- Issue: No 2 (2015)
- Pages: 39-43
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287668
- ID: 287668
Cite item
Open Access
Access granted
Abstract
Inflammatory bowel diseases (IBD) - Crohn's disease and ulcerative colitis (UC) - are characterized by a violation of the interaction of the immune system of the intestine with external factors, primarily the intestinal microbiota. Modern molecular genetic studies of the composition of the intestinal microbiota confirm that IBD are always associated with dysbiosis. Treatment with correction of intestinal microbiota is pathogenetically justified. Probiotics enhance intestinal barrier and affect the local immune system. Research on the effectiveness of probiotics in IBD show mixed results, due to the different design of studies, variety of strains used, and heterogeneous groups of patients. The efficacy of probiotics in UC is more convincing, so they entered the Russian and international recommendations as a drugs for maintaining and achieving remission in mild to moderate disease activity. Probiotics have proven effectiveness in pouchitis. However, probiotic therapy should take into account the possible risk of bacterial translocation in severe forms of IBD, the different effectiveness of probiotic species and strains, and should be based on the results of previous clinical studies on each drug.
Full Text
References
- Lewis J.D., Ruemmele F.M., Wu G.D. Nutrition, Gut Microbiota and Immunity: Therapeutic targets for IBD. Basel, Karger, 2014. Р. 165.
- Fiocchi C. The multifactorial pathogenesis of IBD. - Inflammatory bowel disease - Diagnostic and therapeutic strategies, M., 2006. Р. 21-2.
- Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature insight. 2011;474(7351):298-30.
- Conte M.P., Schippa S., Zamboni I. Gut-associated bacterial microbiota in pediatric patients with inflammatory bowel disease. Gut. 2006;55:1760-67.
- Hill D.A., Artis D. Intestinal bacteria and regulation of immune cell homeostasis. Annul. Rev. Immunol, 2010;8:411-20.
- Hviid A., Svanstrom H., Frisch M. Antibiotic use and Inflammatory bowel disease in childhood. Gut. 2011;60:49-54.
- Kau A.L., Ahern P.P., Griffin N.W. Human nutrition, the gut microbiome and the immune system. Nature insight. 2011;474(7351): 327-36.
- Madsen K.L., Doyle J.S., Jewell L.D., et al. Lactobacillus species prevents colitis in interleukin 10 gene deficient mice. Gastroenterology. 1999;116:1107-14.
- Schultz M., Veltcamp C., Dieleman L.A., et al. continuous feeding of Lactobacillus plantarum attenuates established colitis in interleukin-10 deficient mice. Gastroenterology. 1998;114:A1081.
- Fabia R., Ar'Rajab A., Johansson M.L., et al. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. - Scand. J. Gastroenterol. 1993;28:155-62.
- Malin M., Suolmalainen H., Saxelin M., et al. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann. Nutr. Metab. 1996;40:137-45.
- Prantera C., Scribano M.L., Falasco G., et al. Ineffectiveness of probiotics in preventing reccurence after curative resection for Crohn's diasease:a randomized controlled trial with Lactobacillus GG. Gut. 2002;50: 405-09.
- Plein K., Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in stable phase of Crohn’s disease with special respect to chronic diarrhea - a pilot study. J. Gastroenterol. 1993;31:129-34.
- Guslandi M., Mezzi G., Sorghi M., et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci. 2000;45:1462-64.
- Mallon P.T., McKay D., Kirk S.J., Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2007;4:CD005573.
- Miele E., Pascarella F., Gianetti E., et al. Effect of a probiotic preparation (VCL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol. 2009;104:437-43.
- Sood A., Midha V., Makharia G.K., et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 2009;7:1202-209.
- Naidoo K., Gordon M., Fagbemi A.O., et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2011;12:CD007443.
- Wildt S., Nordgaard I., Hansen U., et al. A randomized duble-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. Lactis BB-12 for maintenance of remission in ulcerative colitis. J. Crohn Colitis. 2011;5:115-21.
- Gionchetti P., Rizzello F., Morselli C., et al. High-dose probiotics for the treatment of active pouchitis. Dis. Colon Rectum. 2007;50:2075-78.
- Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-09.
- Holubar S.D., Cima R.R., Sandborn W.J., Pardi D.S. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane database Syst. Rev. 2010;6:CD001176.
Supplementary files
